Trial Profile
A multicentric, prospective, observational, real‐life study assessing potential benefits of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with with moderate‐to‐severe adult Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2020
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis; Atopic dermatitis; Perennial allergic rhinitis
- Focus Therapeutic Use
- 24 May 2020 New trial record
- 23 Apr 2020 Results published in the Allergy